Notes Payable and Convertible Notes Payable (Details) - USD ($)										1 Months Ended				12 Months Ended		36 Months Ended
	Nov. 01, 2021	Jun. 04, 2021	May 05, 2020	Mar. 02, 2015	Dec. 13, 2013	Jun. 30, 2013	Jun. 29, 2013	May 07, 2012	Dec. 31, 2011	Jun. 25, 2021	May 31, 2018	Sep. 30, 2016	Aug. 31, 2016	Dec. 31, 2021	Dec. 31, 2020	Jun. 03, 2021
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Advance from related party														$ 290,000	$ 2,732,000
Proceeds from promissory notes														410,000	250,000
Convertible notes payable														$ 297,820
Note payable marketing, description														●A marketing fee of $850,000, for development of video content and an electronic press kit which will be used ongoing to support product marketing. This fee is paid with a promissory note of $450,000 and a number of shares of stock of the Company valued at $400,000 in accrued expenses, based on the closing price on the day prior to the effective date; ●Quarterly fees for the first two years of up to $100,000 and issuance of 100,000 shares each quarter, based on sales volumes. The Company has the right to make all the stock payments in cash; and   ●a royalty of 5% of the gross licensed marks sales up to $10,000,000, 7.5% royalty on sales from $10,000,000 to $50,000,0000 and 10% on sales over $50,000,000,payable monthly as well as a 1% of all revenue for all Company products as of the date hereof.  The note payable of $450,000 bears interest at 8% and matures December 31, 2019, unless the Company raises $750,000 through Level Brands prior to that date in which case the Note is to be repaid in full including accrued interest. Accrued interest at December 31, 2021 and 2020 totaled $126,493 and $0, respectively.
Principal balance of the marketing note														$ 450,000	400,000
Accrued expenses														400,000
Related parties															610,000
Outstanding principal										$ 1.15
Discount of fair value warrants issued														54,598
Discount amortization														$ 1,477,895
6% Convertible Debt [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Debt face amount												$ 1,600,000	$ 1,600,000
Aggregate net cash proceeds												$ 1,327,300	$ 1,327,300
Convertible Debentures [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Description of conversion feature														The Convertible Debentures have a stated interest rate of 6% per annum payable quarterly beginning June 30, 2017 and were due two years from the date of issuance, the latest due September 15, 2018 and are convertible into shares of the Company’s common stock at the option of the holder at a conversion price of $12.975 with certain anti-dilutive (reset) provisions and are subject to forced conversion if either i) the volume weighted average common stock price for each of any 10 consecutive trading days equals or exceeds $86.50, or (ii) the Company’s elects to lists a class of securities on a national securities exchange.
Outstanding notes														$ 200,000
Convertible Notes Payable [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Convertible note payable, description		On June 4,2021 as a part of merger, the principal amount and accrued interest were converted into 571,621 shares of Common Stock, fully converting the notes and accrued interest as of December 31, 2021.
Senior Notes [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Secured notes payable											$ 1,000,000
Accrued interest										$ 603,778					510,444
Granted (in Shares)														64,604
Granted year														2 years
Warrants exercisable														$ 2.0587
Conversion feature														24,775
Unamortized discount														69,033
Discount amortization														10,239
CJY Holdings Ltd [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Accrued interest														23,485	0
Notes payable total amount														$ 270,000
Interest rate														10.00%
Notes payable														$ 270,000	0
Dr David Platt [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Advance from related party									$ 257,820
Interest rate							6.50%
Dr David Platt [Member] | Promissory Note [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Advance from related party								$ 20,000
Interest rate						6.50%
Proceeds from promissory notes								$ 40,000
Senior Secured Convertible Note [Member] | Senior Notes [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Note payable and senior secured convertible notes, description										On June 25, 2021, the Company and the $1.0 secured million note payable Holder entered into exchange agreement, whereby the company issued the Holder a Senior Secured Convertible Note in the principal amount of $1,603,778 with a maturity date of June 18, 2023. On the maturity date, the Company shall pay to the Holder an amount in cash representing 115% of all outstanding Principal. No interest shall accrue thereunder unless and until an Event of Default has occurred. At any time after the Issuance Date, this Note may be convertible into validly, fully paid and non-assessable shares of Common Stock. As an incentive to enter into the agreement, the noteholder was also granted 779,025 2-year warrants exercisable at $2.0587. The issuance of the note and warrants resulted in a loss on modification of debt of $2,385,204. As of December 31, 2021, the note balance was $1,603,778. On June 25, 2021, the Company and Gold Blaze Limited Vistra Corporate Services entered into exchange agreement, where the company issued the Gold Blaze Limited Vistra Corporate Services Senior Secured Convertible Note in the principal amount of $500,000 with a maturity date of June 25, 2023. On the maturity date, the Company shall pay to the Holder an amount in cash representing 115% of all outstanding Principal. No interest shall accrue thereunder unless and until an Event of Default has occurred. At any time after the Issuance Date, this Note may be convertible into validly, fully paid and non-assessable shares of Common Stock. As an incentive to enter into the agreement, the noteholder was also granted 242,872 2-year warrants exercisable at $2.0587. The issuance of the note and warrants resulted in a discount from the beneficial conversion feature totaling $500,000. As of December 31, 2021, the note was shown net of unamortized discount of $375,000. Discount amortization for the year ended December 31, 2021 was $125,000. In June 25, 2021, the Company issued a Senior Secured Convertible Note to HT Investment MA LLC for a principal amount $5.0 million and maturity date of June 25, 2023. On the maturity date, the Company shall pay to the Holder an amount in cash representing 115% of all outstanding Principal. No interest shall accrue thereunder unless and until an Event of Default has occurred. At any time after the Issuance Date, this Note may be convertible into validly, fully paid and non-assessable shares of Common Stock. As an incentive to enter into the agreement, the noteholder was also granted 2,428,717 2-year warrants exercisable at $2.0587. The issuance of the note and warrants resulted in a discount from the beneficial conversion feature totaling $4,500,000. Funds received were $4,500,000 net of an original issue discount of $500,000. As of December 31, 2021, the note was shown net of unamortized discount of $3,750,000. Discount amortization for the year ended December 31, 2021 was $1,250,000. In September 27, 2021, the Company issued a Senior Secured Convertible Note to Dr. Harold Parnes for a principal amount $1.2 million and maturity date of September 27, 2023. On the maturity date, the Company shall pay to the Holder an amount in cash representing 115% of all outstanding Principal. No interest shall accrue thereunder unless and until an Event of Default has occurred. At any time after the Issuance Date, this Note may be convertible into validly, fully paid and non-assessable shares of Common Stock. As an incentive to enter into the agreement, the noteholder was also granted 582,892 2-year warrants exercisable at $2.0587. The issuance of the note and warrants resulted in a discount from the beneficial conversion feature totaling $222,534 and a discount from the relative fair value of warrants issued of $494,802. As of December 31, 2021, the note was shown net of unamortized discount of $624,680. Discount amortization for the year ended December 31, 2021 was $92,656. In September 27, 2021, the Company issued a Senior Secured Convertible Note to Steve Schrader for a principal amount $131 thousand and maturity date of September 27, 2023. On the maturity date, the Company shall pay to the Holder an amount in cash representing 115% of all outstanding Principal. No interest shall accrue thereunder unless and until an Event of Default has occurred. At any time after the Issuance Date, this Note may be convertible into validly, fully paid and non-assessable shares of Common Stock.
Convertible Notes Payable [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Accrued interest														$ 55,008	0
Stock Issued																$ 8,700,000
Related parties																7,700,000
Interest rate														15.00%
Warrant interest rate														30.00%
Special preferred stock														$ 0.32276
Notes convert, per share (in Dollars per share)														$ 18.613
Accrued interest															1,429,327	$ 1,960,116
Notes Payable [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Accrued interest														$ 127,575	0
Notes payable, description				On March 2, 2015, the Board of Directors voted to reduce the amount that Dr. Platt was required to reimburse the Company to $82,355 and to offset this amount against interest accrued in respect of the outstanding note payable to Dr. Platt. In addition, the Board determined that Dr. Platt would be charged interest related to the $182,697 indemnification payment since funds were received by Dr. Platt in July 2014. The Board of Directors concluded the foregoing constituted complete satisfaction of Dr. Platt’s indemnification by the Company. Accordingly, the Company recorded the reduction in accrued interest through equity during the year ended December 31, 2015. As of December 31, 2021 and 2020, the balance of the notes payable to Dr. Platt totaled $277,821 and are included in notes payable	In December 2013, the Board of Directors agreed to indemnify Dr. Platt for legal costs incurred in connection with an arbitration (now concluded) initiated before the American Arbitration Association by Galectin Therapeutics, Inc. (formerly named Pro-Pharmaceuticals, Inc.) for which Dr. Platt previously served as CEO and Chairman. Galectin sought to rescind or reform the Separation Agreement entered into with Dr. Platt upon his resignation from Galectin to remove a $1.0 million milestone payment which Dr. Platt asserted he was entitled to receive and to be repaid all separation benefits paid to Dr. Platt. The Company initially capped the amount for which it would indemnify Dr. Platt at $150,000 in December 2013 and Dr. Platt agreed to reimburse the indemnification amounts paid by the Company should he prevail in the arbitration. The Board decided to indemnify Dr. Platt after considering a number of factors, including the scope of the Company’s existing indemnification obligations to officers and directors and the potential impact of the arbitration on the Company. In May 2014, the Board approved a $50,000 increase in indemnification support, solely for the payment of outside legal expenses. The Company recorded a total of $182,697 in costs associated with Dr. Platt’s indemnification, of which $119,401 was expensed in the year ended December 31, 2013 and of which $63,296 was expensed in the year ended December 31, 2014. In July 2014, the arbitration was concluded in favor of Dr. Platt, confirming the effectiveness of the separation agreement and payment was made to Dr. Platt in July 2014. On March 2, 2015, the Board of Directors voted to reduce the amount that Dr. Platt was required to reimburse the Company to $82,355 and to offset this amount against interest accrued in respect of the outstanding note payable to Dr. Platt. In addition, the Board determined that Dr. Platt would be charged interest related to the $182,697 indemnification payment since funds were received by Dr. Platt in July 2014.
Paycheck Protection Program [Member]
Notes Payable and Convertible Notes Payable (Details) [Line Items]
Interest rate			1.00%
Accrued interest														$ 0	$ 2,636
Cost			$ 402,154
Interest rate			25.00%
Principal	$ 402,154
Interest	$ 6,088